Thrivent Financial for Lutherans
ARQT icon

Thrivent Financial for Lutherans’s Arcutis Biotherapeutics ARQT Stock Holding History

Thrivent Financial for Lutherans’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-33,914
Closed -$373K – 2465
2023
Q1 		$373K Hold
33,914
– – ﹤0.01% 2237
2022
Q4 		$502K Hold
33,914
– – ﹤0.01% 2115
2022
Q3 		$649K Buy
+33,914
New +$768K ﹤0.01% 1937
2021
Q4 		– Sell
-10,370
Closed -$248K – 2461
2021
Q3 		$248K Buy
+10,370
New +$237K ﹤0.01% 2385

Other funds holding ARQT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Thrivent Financial for Lutherans's ARQT Position: Q2 2023 in Review

Thrivent Financial for Lutherans sold out of Arcutis Biotherapeutics (ARQT) in Q2 2023, closing a stake of 33,914 shares — an estimated $373K sold.

Thrivent Financial for Lutherans first reported a position in ARQT in Q3 2021 and held it in 4 quarters. The position peaked at $649K in Q3 2022. 136 funds tracked by Wall St. Rank hold ARQT as of Q2 2023.

  • Thrivent Financial for Lutherans reported no remaining Arcutis Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 33,914 Arcutis Biotherapeutics shares in Q2 2023, an estimated $373K.
  • Thrivent Financial for Lutherans first reported a position in Arcutis Biotherapeutics in Q3 2021 and held it in 4 quarters.
  • Thrivent Financial for Lutherans's Arcutis Biotherapeutics position peaked at $649K in Q3 2022.
  • 136 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2023.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2023, filed 14 Aug 2023.